MedTrace Logo

Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

NCT00792688 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2021-10-28

Study results available
· View outcomes & findings →

Summary

The primary objectives of this study are to evaluate safety and efficacy of topically applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%) in promoting wound healing in cosmetic surgery patients undergoing Carbon Dioxide Laser Skin Resurfacing (CO2 LSR) of the lower eyelids. The study will observe the effects of the topical agent over the course of 1 month following the initial treatment.

Conditions

  • Wounds

Interventions

DRUG

GLYC-101 Gel (0.1%)

Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.

DRUG

GLYC-101 Gel (1.0%)

Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.

DRUG

GLYC-101 Placebo

Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.

Sponsors & Collaborators

  • TR Therapeutics

    lead INDUSTRY

Principal Investigators

  • John Joseph, MD · The Clinical Testing Center of Beverly Hills

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00792688 on ClinicalTrials.gov